The importance of antenatal prevention of RhD immunisation in the first pregnancy
- PMID: 24887219
- PMCID: PMC4111824
- DOI: 10.2450/2014.0167-13
The importance of antenatal prevention of RhD immunisation in the first pregnancy
Abstract
Background: The aim of this study was to examine which pregnancies are associated with RhD immunisation and haemolytic disease of foetus and newborn (HDFN) when postnatal RhD prophylaxis is applied.
Material and methods: This retrospective cohort study included pregnancies with RhD immunisation; each of the pregnant women received anti-D immunoglobulin after delivery, miscarriage or invasive antenatal diagnostic procedures. For each pregnancy we analysed the order of pregnancy that caused immunisation as well as the order of the monitored pregnancy and whether the anti-D antibodies caused HDFN.
Results: Anti-D antibody was detected in 1.2% of RhD-negative pregnancies. Out of 89 monitored pregnancies, 56 (63%) were immunised by the first pregnancy, 21 (24%) by the second one, and 12 (13%) by subsequent pregnancies. HDFN occurred in 28 cases; 25 of them were the consequence of the immunisation in the first pregnancy. The most severe cases of HDFN, perinatal death (n=2) and intrauterine transfusion (n=7) were consequence of immunisation during the first pregnancy. Significantly more cases of HDFN were caused by immunisation in the first pregnancy than by immunisation in subsequent pregnancies (χ(2)=12, p<0.01).
Conclusion: RhD immunisation could be reduced in more than half cases by administering anti-D immunoglobulin at the beginning of the third trimester of pregnancy, especially the first pregnancy.
Similar articles
-
Disease severity in subsequent pregnancies with RhD immunization: A nationwide cohort.Vox Sang. 2024 Aug;119(8):859-866. doi: 10.1111/vox.13651. Epub 2024 May 21. Vox Sang. 2024. PMID: 38772910
-
Cost-effectiveness of first trimester non-invasive fetal RHD screening for targeted antenatal anti-D prophylaxis in RhD-negative pregnant women: a model-based analysis.BJOG. 2016 Jul;123(8):1337-46. doi: 10.1111/1471-0528.13801. Epub 2015 Dec 10. BJOG. 2016. PMID: 26663771
-
Targeted routine antenatal anti-D prophylaxis in the prevention of RhD immunisation--outcome of a new antenatal screening and prevention program.PLoS One. 2013 Aug 6;8(8):e70984. doi: 10.1371/journal.pone.0070984. Print 2013. PLoS One. 2013. PMID: 23940682 Free PMC article.
-
Rhesus D Prophylaxis: When and Why We Give Rhesus D Immunoglobulin.Obstet Gynecol Surv. 2025 May;80(5):315-324. doi: 10.1097/OGX.0000000000001391. Obstet Gynecol Surv. 2025. PMID: 40328690 Review.
-
The scientific basis of antenatal prophylaxis.Br J Obstet Gynaecol. 1998 Nov;105 Suppl 18:11-8. doi: 10.1111/j.1471-0528.1998.tb10286.x. Br J Obstet Gynaecol. 1998. PMID: 9863973 Review.
Cited by
-
Recombinant anti-D for prevention of maternal-foetal Rh(D) alloimmunization: a randomized multi-centre clinical trial.Obstet Gynecol Sci. 2020 May;63(3):315-322. doi: 10.5468/ogs.2020.63.3.315. Epub 2020 Apr 21. Obstet Gynecol Sci. 2020. PMID: 32489976 Free PMC article.
-
Blood Group Rhesus D-negativity and Awareness Toward Importance of Anti-D Immunoglobulin Among Pregnant Women in Bisha, Saudi Arabia.Cureus. 2020 Feb 19;12(2):e7044. doi: 10.7759/cureus.7044. Cureus. 2020. PMID: 32128293 Free PMC article.
-
Anti-D Antibodies in Pregnant D Variant Antigen Carriers Initially Typed as RhD.Transfus Med Hemother. 2016 Nov;43(6):419-424. doi: 10.1159/000446816. Epub 2016 Oct 14. Transfus Med Hemother. 2016. PMID: 27994529 Free PMC article.
-
A Multicenter, Randomized, Open-Label Trial Comparing the Efficacy and Safety of Monoclonal Anti-Rh (D) Immunoglobulin with Polyclonal Anti-Rh (D) Immunoglobulin for the Prevention of Maternal Rh-Isoimmunization.J Obstet Gynaecol India. 2019 Oct;69(5):420-425. doi: 10.1007/s13224-019-01234-2. Epub 2019 Jun 3. J Obstet Gynaecol India. 2019. PMID: 31598044 Free PMC article.
-
Anti-D monoclonal antibodies from 23 human and rodent cell lines display diverse IgG Fc-glycosylation profiles that determine their clinical efficacy.Sci Rep. 2020 Jan 30;10(1):1464. doi: 10.1038/s41598-019-57393-9. Sci Rep. 2020. PMID: 32001734 Free PMC article.
References
-
- Klein H, Anstee D. London: Blackwell Science, editor. Mollison’s Blood Transfusion in Clinical Medicine. 2005. Hemolytic disease of the fetus and newborn; pp. 496–545.
-
- Bowman JM. RhD hemolytic disease of the newborn. N Engl J Med. 1998;334:1775–7. - PubMed
-
- Kumpel BM. On the immunologic basis of Rh immuneglobulin (anti-D) prophylaxis. Transfusion. 2006;46:1652–6. - PubMed
-
- Crowther CA, Keirse MJ. Anti-D administration in pregnancy for preventing rhesus alloimunization. Cochrane Database Syst Rev. 2000;(2):CD000020. - PubMed
-
- Fung Kee Fung K, Eason E, Crane J, et al. Prevention of Rh alloimunization. J Obstet Gynaecol Can. 2003;25:765–73. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical